Figure 3: Clenbuterol ameliorates the life span and motor function of SBMA knock-in mice. | Scientific Reports

Figure 3: Clenbuterol ameliorates the life span and motor function of SBMA knock-in mice.

From: Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes

Figure 3

(A) Kaplan-Meier analysis of survival of control (CTR, wild type, square) and AR113Q (circle) mice treated with vehicle (red) and clenbuterol (Clenb, 1 mg/kg, green; 2 mg/kg, blue). (B) Body weight analysis of CTR and AR113Q mice treated with vehicle (CTR, black; AR113Q, red) and clenbuterol (2 mg/kg; CTR, grey; AR113Q, blue). Graph, mean ± SEM. (C) Rotarod analysis of motor coordination in CTR and AR113Q mice, n = as in (B). Graph, mean ± SEM. Week 24: *p = 0.015 CTR-vehicle vs AR113Q-vehicle. Week 25: *p = 0.002 CTR-vehicle vs AR113Q-vehicle, #p = 0.005 AR113Q-vehicle vs AR113Q-clenbuterol. (D) Grip strength analysis of CTR and AR113Q mice treated as in (B). Graph, mean ± SEM. Week 22: *p = 0.007 CTR-vehicle vs AR113Q-vehicle, #p = 0.026 AR113Q-vehicle vs AR113Q-clenbuterol. Week 23: *p = 0.028 CTR-vehicle vs AR113Q-vehicle, #p = 0.003 AR113Q-vehicle vs AR113Q-clenbuterol. Week 24: *p = 0.007 CTR-vehicle vs AR113Q-vehicle. Week 25: *p = 0.03 CTR-vehicle vs AR113Q-vehicle, #p = 0.06 AR113Q-vehicle vs AR113Q-clenbuterol. (E) In vivo force generation of gastrocnemius muscle measured in live 180-day-old AR113Q and CTR mice treated as in (B). Graph, mean ± SEM, n = 4 mice.

Back to article page